Forty-two patients were treated with intravenous cefoxitin, a new cephamycin antibiotic. These patients had postoperative abdominal sepsis (26), intrathoracic infections (6), urinary tract infections (5), gram-negative bacterial meningitis (2), septic arthritis (1), epidural abscess (1) and isolated septicemia (1). The antibacterial spectrum of cefoxitin was found to be one which included all gram-positive organisms except enterococci, most gram-negative organisms except Pseudomonas aeruginosa, and almost all of the important anaerobic organisms. The only five treatment failures included one patient with empyema and one with septic arthritis, both caused by Serratia marcescens, initially only moderately susceptible to cefoxitin, which subsequently developed increased resistance, two patients with contaminated intravenous catheters, and one patient with epidural abscess and cerebritis, who was treated late in the course. There was one serious clinical superinfection with P. aeruginosa. The drug levels noted in the pus and joint fluid were half to two-thirds of the simultaneous serum level. In inflamed meninges, up to 30% of the serum level was noted in the cerebrospinal fluid, and as the process resolved, 10 to 15% was noted. Toxicity of cefoxitin was mild and constituted skin rash in three patients (7%) and phlebitis in eight (19%).
Cefoxitin (Mefoxin) is a new semisynthetic beta-lactam antibiotic derived by a chemical modification of cephamycin C. A methoxy group takes the place of the hydrogen atom at the 7- alpha position of the cephalothin molecule, and a carbamoyloxy group takes the place of the acetoxy radical at the 3-methyl position. These particular substitutions confer on cefoxitin the property of resistance to bacterial beta-lactamases, including those of Bacteroides (8, 12) . This property should make this new antibiotic useful in the treatment of abdominal and pulmonary abscesses, where recent work has shown a mixed bacterial flora, predominantly anaerobic, to be the most common etiological agents isolated (2, 4, 5, 7, 13) . We set out to conduct a clinical trial of this new agent in patients with such infections who had failed to respond to therapy with currently used antibiotics or who appeared unable to tolerate them.
MATERIALS AND METHODS
The drug was available in 1-g vials in granule form of the sodium base (Mefoxin) and was easily dissolved 6 to 12 g/day in divided doses, and a maximum dose of 18 g was also used.
The patients were from the private and ward service cases of the Jewish Hospital and Medical Center of Brooklyn. The Brooklyn Hospital and Downstate Medical Center-Kings County Hospital, Brooklyn, N. Y., each contributed one patient. The criteria for inclusion in the study were as follows: (i) mixed or anaerobic infection failing to respond to previous therapy; (ii) multiply resistant bacterial infections, again which had failed to respond to previous therapy; and (iii) gram-negative meningitides not susceptible to ampicillin or chloramphenicol.
Women who were pregnant and children were excluded. An informed consent was signed by either the patient or the responsible relative. All patients had prior base line cultures and urinalysis, hemoglobin estimation, total and differential leukocyte counts, platelet counts, and estimations of serum glucose, electrolytes, blood urea nitrogen, creatinine, total bilirubin, alkaline phosphatase, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, and lactic dehydrogenase; these were repeated during and after the study. The (11) . The susceptibility testing to antibiotics including cefoxitin was determined for the aerobes by the Bauer-Kirby method (3), and a considerably modified one was used for anaerobes. For the anaerobes, brain heart infusion agar containing 0.03% palladium chloride and enriched with 5% fresh sheep blood wasused to make the plates, which were maintained in a deoxygenated atmosphere until use. The zone size was checked against the tube dilution minimum inhibitory concentrations (MICs) by using Mueller-Hinton broth for the aerobes and deoxygenated brain heart infusion broth for the anaerobes; this was done for both cefoxitin and cephalothin. The volume of broth was 1 ml, to which was added 0.05 ml of inoculum of an overnight (aerobes) or 24 to 48-h culture (anaerobes); incubation was at 37°C for 24 h (aerobes) or 24 to 48 h (anaerobes); and the anaerobic cultures were held in GasPak jars in a deoxygenated environment during incubation. The miniimum bactericidal concentrations (MBCs) were estimated by noting the highest dilution showing 99% or more reduction in colony counts compared with the controls. Where feasible, a biological assay of cefoxitin in the serum and the appropriate body secretions was done by the agar diffusion method (1) by using the Merck strain of S. aureus (25923).
Determinations of the stability of cefoxitin in pus were made in the following manner. Three specimens of pus from abscesses of patients receiving cefoxitin were assayed for cefoxitin on receipt at the laboratory, incubated at 37°C, and reassayed each hour for 8 a rheumatoid knee (no. 41), with subsequent development of increased resistance to cefoxitin; one had a secondary Serratia invasion of an empyema cavity (no. 29), again with the development of increased resistance; and one had an epidural abscess (no. 40), originating in a purulent pansinusitis with inadequate drainage, and was started on the drug only late in the course. In addition, patient no. 30, who had responded satisfactorily, then had severe blood loss through gastrointestinal bleeding; shock developed and a P. aeruginosa septicemia was noted as an agonal event. This appeared to be the only clinical superinfection observed.
Twenty-five patients had intraabdominal infections (case no. 1 was suspected but not confirmed), of which all but five were postoperative complications. All except two had preceding antibiotic therapy for at least 1 week. Ten patients were on a combination of gentamicin, tobramycin, or amikacin and cephalothin, five were on ampicillin or cephalothin alone, three were on gentamicin and clindamycin, three were on penicillin and kanamycin, and one each were on oral penicillin, clindamycin, and chloramphenicol. Surgical drainage from the primary procedure or secondary one was present in 17 cases. In total, surgical drainage supplemented cefoxitin therapy in all but five (no. 4, 6, 9, 12, and 23). These five patients were all postoperative cases strongly suspected of having pelvic or intraabdominal abscesses. All of these patients responded satisfactorily. There were six patients with intrathoracic infections, three with empyema, and three with pneumonia. One patient with empyema (no. 32) and the two with Klebsiella pneumoniae pneumonia were cleared completely. The second patient with empyema complicating systemic lupus erythematosus (no. 30) already mentioned had a complete bacteriological response of the infection, but died abruptly after surgery for a massive gastrointestinal bleeding with a terminal Pseudomonas septicemia. The third patient with empyema (no. 29) responded well initially, but the moderately resistant Serratia (MBC, 25 ,ug/ml) (apparently introduced through the chest tube), despite levels of cefoxitin in the pus about three times the initial MBC, became increasingly resistant, developing an MBC well over 100 ,Ag/ml. The fifth patient, a cirrhotic with a pneumonia presumed to be caused by the same organism that was recovered from the blood, Enterobacter cloacae, in fact proved to be resistant to treatment until the intravenous route was discontinued. This was the second of the two cases, previously mentioned, in which a contaminated intravenous catheter was the cause of the bacteremia. Both patients with Five patients with urinary tract infections responded promptly, as urinary concentrations of cefoxitin were in the thousands of micrograms per milliliter of urine. Three of these infections were produced by Serratia marcescens with MBCs in the range of 25 to 37.5 ,ug/ml.
Three patients had intracranial infections, of which two were gram-negative rod meningitis (Escherjchia coli and K. pneumoniae, each with an MBC of 6.25 ,ug/ml of cefoxitin), both responding completely to treatment with cefoxitin. Cefoxitin was administered together with oral probenecid. The cerebrospinal fluid concentrations were found to be in the range of 25 to 30 ,ig/ml with active inflammation and 10 to 15 ,ug/ml after this period. The third patient had a purulent pansinusitis, which led to the spread of the infection to the epidural space. Drainage of pus was inadequate, and the patient died shortly after cefoxitin treatment was started. The concentration of antibiotic in the pus aspirated shortly before death was 35 ,ug/ml.
One patient with a Serratia arthritis complicating a rheumatoid knee joint, had, after a period of initial response, a relapse. The strain was initially moderately resistant (MBC, 37.5 ,ug/ml) and became totally resistant subsequently (MBC > 100 ,ug/ml) (similar to case no. 29). This phenomenon could easily be recreated in vitro by exposing the initial strain to higher and higher concentrations of the drug, in broth, with subculturing of surviving colonies; in the passages the MBC was raised to >100 ,ug/ml. One patient had an E. coli septicemia, probably enteric in origin, and the blood cultures reverted to negative within 24 h of starting treatment with cefoxitin. In all, 12 patients were septicemic; this includes the two intravenous catheter infections. ,ug/ml for urine. In general, 40 to 50% of the serum levels are noted in the various body compartments. The assays in pus and body fluids were felt to be accurate because of the remarkable stability of cefoxitin in these fluids. Incubation in pus or cerebrospinal fluid at 37°C for VOL. 14, 1978 872 NAIR AND CHERUBIN more than 24 h resulted in no decrease in the activity, whereas ampicillin, for example, was completely degraded in pus with a 24-h incubation time.
In patients with normal renal function (creatinine, cl mg/dl), the drug was so rapidly excreted by the kidneys that, at the end of 2 h, virtually no drug was detectable in the serum. Hence, a dosage regimen of the drug every 4 h was considered to be satisfactory. On the other hand, in patients with increasing degrees ofrenal insufficiency, higher and higher levels were detectable in the serum at the end of 3 and 4 h (Fig. 2) . The concurrent administration of probenecid in six patients with normal renal function, including the ones with meningitis, helped produce prolonged serum levels 2 to 4 h after an infusion, similar to what was noted in patients with renal insufficiency (i.e., 45 to 100 ,ug/ml at 2hand5to25,ug/mlat4h). Table 2 shows a comparison of the MICs of both cefoxitin and cephalothin for the important clinical isolates. A higher proportion of Bacteroides and E. coli are susceptible to cefoxitin than are susceptible to cephalothin, and for Serratia, lower concentrations of cefoxitin than cephalothin are found to be inhibitory. Both the drugs seem to be equally active against Klebsiella, Enterobacter, and Proteus species.
The anaerobic isolates from this study as well as from other patients were utilized for making a comparison of their tube dilution MICs with their agar plate zone diameters of inhibition (Fig. 3) . The correlation coefficients were calculated for Bacteroides, Clostridia, and for miscellaneous anaerobes. The correlation was the best for Bacteroides (nearly all B. fragilis) (0.7), almost as good for the miscellaneous anaerobes (0.5), and the least good for Clostridia (0.2). On the whole, however, a 25-mm zone diameter would seem to divide all the anaerobes fairly well into those with an MIC of 12.5 ug/ml or less, and those with one of 25 ,ug/ml or more.
Toxicity. Cefoxitin was well tolerated by most patients. Eight patients (19%) had mild phlebitis at the site of injection, and these were not severe enough to warrant discontinuation of therapy. Three patients (7%) had a mild skin rash, one of whom had a urticarial rash lasting only a short time after a bolus injection of the drug and tolerated subsequent infusions very well. There was no evidence of drug fever or eosinophilia or of any hepatic or renal toxicity.
In those with pre-existing malfunction of these organs, no worsening was noted. DISCUSSION Cefoxitin is a new antibiotic ofthe cephamycin C family and is chemically a 7-methoxylated ANTIMICROB. AGENTS CHEMOTHER.
cephalosporin. Its well-known differences from cephalothin include its resistance to bacterial beta-lactamases and activity against most anaerobes, including B. fragilis. This paper details the clinical and microbiological study of a group of 42 patients with abdominal, thoracic, intracranial, joint, and urinary tract infections, the majority of them difficult to treat from the point of view of failure on previous antibiotic therapy, thus affording an opportunity to utilize what appears to be beneficial properties of the antibiotic and to evaluate its safety for general use.
Of the 42 patients treated, all except 5 (88%) were considered to have complete therapeutic responses. Because most of the patients had been receiving forms of combination drug therapy which are generally recommended, this would make the response to cefoxitin worthy of note by itself. Two cases of Serratia infection (empyema, no. 29; joint infection, no. 41) were moderately resistant to cefoxitin to begin with and became totally so as treatment progressed. Because this was easily reproduced in the laboratory, it may signal that Serratia superinfections could become a clinically important superinfection problem with cefoxitin therapy. Another case developed a Pseudomonas septicemia as a terminal event, although her original infection was completely resolved, and this also may prove to be a serious problem when cefoxitin is used alone.
The chance finding of a high spinal fluid level of cefoxitin in patient no. 24 led us to the subsequent successful treatment of two cases of gram-negative meningitis with intravenous cefoxitin (no. 38 and 39). The organisms were E. coli and K. pneumoniae, both resistant to ampicillin and chloramphenicol. The alternative to cefoxitin would have been repeated intrathecal injections of gentamicin. Both patients received oral probenecid during the entire period of treatment with cefoxitin. The levels of the drug observed in the spinal fluid (25 to 30 ,ug/ml) were remarkable and indicate that this agent may be potentially useful for central nervous system infections.
Cefoxitin is predominantly excreted unchanged (98%) in the urine (6) . This made it possible to treat five patients with urinary tract infections with cefoxitin, three of them caused by S. marcescens with MBCs in the range of borderline resistance (no. 35, 36, and 37). Urinary concentrations were observed to be well over 2,000 ,ug/ml of urine. In patients with renal failure, higher blood levels were possible with smaller doses (Fig. 2) . Although a dose reduction is practical, there was no evidence of cumulative toxicity or worsening of existing renal functions where the dose was not reduced.
Comparison of mean cefoxitin levels in joint fluid, pus, and urine with simultaneous serum levels (observations were performed on three or more subjects 1 h after an infusion of2 g). One half to two-thirds of serum level appears in pus (63 pg/mi; range, 35 to 83 pg/ml) andjoint fluid (43 pg/ml; range, 25 to 110 pg/ml). In urine the drug is concentrated many-fold (mean, >2,000 pg/ml). teus (0%), and Serratia (28%) and activity for Bacteroides were very similar to that of clindamycin and chloramphenicol. It is clear that, with these advantages and a toxicity similar to that of cephalothin, cefoxitin is likely to prove useful in the prolonged treatment of abscesses of mixed bacterial etiology, now considered to be the major flora in these conditions, supplementing surgical drainage; in addition it shows a potential for some of the difficult central nervous system infections. The choice of antibiotic therapy for gram-negative rod meningitis, unresponsive to ampicillin and chloramphenicol, is far from easy, and most current regimens include intrathecal administration of potentially nephrotoxic agents. Further clinical trials in this area with cefoxitin might help to simplify the treatment of these infections.
